Evotec SE (SWX:EVT)

Market Cap	735.72M -31.4%
Revenue (ttm)	707.59M -2.7%
Net Income	-148.74M
EPS	-0.84
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	26.96 - 26.96
52-Week Range	3.85 - 26.96
Beta	n/a
RSI	1.88
Earnings Date	Apr 8, 2026

About Evotec SE

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic disease...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 4,788
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: EVT

Financial Performance

In 2024, Evotec SE's revenue was 796.97 million, an increase of 1.99% compared to the previous year's 781.43 million. Losses were -196.08 million, 133.7% more than in 2023.

Financial numbers in EUR